Saturday, March 25, 2023 | Back issues
Courthouse News Service Courthouse News Service

Pharma Merger

CHICAGO - A $675 million acquisition deal by Actavis undervalues Durata Therapeutics, just after its successful launch of Dalvence, shareholders claim in court.

Read the Top 8

Sign up for the Top 8, a roundup of the day's top stories delivered directly to your inbox Monday through Friday.